Biogen Inc BIIB:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/03/24 EDT

217.78

+0.27 (+0.12%)

Volume

33,795

217.51

+4.00 (+1.87%)

Volume

1,109,934

52 week range

189.44 - 319.76

Open215.30
Day High217.88
Day Low213.11
Prev Close213.51
52 Week High319.76
52 Week High Date06/12/23
52 Week Low189.44
52 Week Low Date04/19/24

Key Stats

Market Cap31.669B
Shares Out145.60M
10 Day Average Volume1.60M
Dividend-
Dividend Yield-
Beta-0.03
YTD % Change-15.94

KEY STATS

Open215.30
Day High217.88
Day Low213.11
Prev Close213.51
52 Week High319.76
52 Week High Date06/12/23
52 Week Low189.44
52 Week Low Date04/19/24
Market Cap31.669B
Shares Out145.60M
10 Day Average Volume1.60M
Dividend-
Dividend Yield-
Beta-0.03
YTD % Change-15.94

RATIOS/PROFITABILITY

EPS (TTM)8.00
P/E (TTM)27.18
Fwd P/E (NTM)14.12
EBITDA (TTM)2.652B
ROE (TTM)8.04%
Revenue (TTM)9.663B
Gross Margin (TTM)75.03%
Net Margin (TTM)12.08%
Debt To Equity (MRQ)42.99%

EVENTS

Earnings Date07/23/2024(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Biogen Inc

Lilly assures investors it can overcome the high-quality problem of too much demandApril 30, 2024CNBC.com
3-Stock Lunch: TXN, BIIB & CMGApril 24, 2024CNBC.com
Stocks making the biggest moves midday: Tesla, Hilton, Boeing, Mattel and moreApril 24, 2024CNBC.com
Stocks making the biggest moves premarket: Boeing, Tesla, Visa, Airbnb and moreApril 24, 2024CNBC.com
Biogen tops profit estimates as cost cuts take hold, Leqembi launch picks upApril 24, 2024CNBC.com

Content From Our Affiliates

Biogen price target raised to $342 from $339 at HSBCMay 3, 2024TipRanks
Biogen reports progress on Corporate Responsibility PrioritiesMay 2, 2024TipRanks
Biogen Reports Progress on Corporate Responsibility PrioritiesMay 2, 2024TipRanks
Sage Therapeutics price target lowered to $15 from $26 at RBC CapitalApril 26, 2024TipRanks
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Dexcom (DXCM) and Herbalife (HLF)April 26, 2024TipRanks

Profile

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include...

Caroline Dorsa

Independent Chairman of the Board

Christopher Viehbacher

President, Chief Executive Officer, Director

Michael McDonnell CPA

Chief Financial Officer, Executive Vice President

Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

Adam Keeney Ph.D.

Executive Vice President, Head of Corporate Development

Address

225 Binney Street

Cambridge, MA

02142

United States

https://www.biogen.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
MRNA Moderna Inc	125.00	-0.59	-0.47%
ILMN Illumina Inc	117.93	-6.06	-4.89%
BNTX Biontech SE	92.72	+0.48	+0.52%
GRFS Grifols SA	6.57	+0.18	+2.82%
CRL Charles River Laboratories International Inc	233.47	+3.58	+1.56%